Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Oncotarget · 2018 · PMC5839396 · PMID 29515765

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

This MIPSSR model showed a trend to improved prognostic discrimination potential compared to IPSS-R as indicated by higher Dxy values (0.46 vs 0.43) and Cox model analysis (c-index 0.73 vs 0.71) ( Supplementary Table 10, Supplementary Material ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.